This review provides an overview of our present state of knowledge using manganese oxide (MnO_x)-based catalysts for toluene abatement in PPC (Post plasma-catalysis) configuration. The context of this study is concisely sum-up. After briefly screening the main depollution methods, the principles of PPC are exposed based on the coupling of two mature technologies such as NTP (Non thermal plasma) and catalysis. In that respect, the presentation of the abundant manganese oxides will be firstly given. Then in a second step the main features of MnO_x allowing better performances in the reactions expected to occur in the abatement of toluene in PPC process are reviewed including ozone decomposition, toluene ozonation, CO oxidation and toluene total oxidation. Finally, in a last part the current status of the applications of PPC using MnO_x on toluene abatement are discussed. In a first step, the selected variables of the hybrid process related to the experimental conditions of toluene abatement in air are identified. The selected variables are those expected to play a role in the performances of PPC system towards toluene abatement. Then the descriptors linked to the performances of the hybrid process in terms of efficiency are given and the effects of the variables on the experimental outcomes (descriptors) are discussed. The review would serve as a reference guide for the optimization of the PPC process using MnO_x-based oxides for toluene abatement.

Background. The 2009 H1N1 pandemic viruses are genetically similar to A/New Jersey/76 H1N1 virus (NJ/76), the strain selected for the 1976 “swine flu” vaccines. Approximately 45 million people in the United States were vaccinated against NJ/76 30 years ago, but the impact of this nationwide immunization on the current pandemic is largely unknown. Methods. Archived human serum samples collected during the 1976 swine flu vaccine trials were assessed for cross-reactive antibody responses to the 2009 H1N1 pandemic viruses. Results. Administration of an NJ/76 monovalent vaccine or the combination of a bivalent vaccine (NJ/76 H1N1 and A/Victoria/75 H3N2) plus a B/Hong Kong/72 monovalent vaccine increased hemagglutinin inhibition (HAI) and neuraminidase inhibition (NAI) antibodies cross-reacting with the 2009 H1N1 pandemic viruses. We showed that cross-reactive human HAI antibodies elicited by the 1976 swine flu vaccination played a dominant role in protecting recipient mice against the wild-type A/California/04/2009. Cross-reactive human NAI antibodies were also protective in recipient mice after a lethal challenge with a hemagglutinin mismatched virus bearing the A/California/04/2009 neuraminidase gene. Transfer of human serum samples with an original HAI titer of 43 or an original NAI titer of 472 was estimated to protect 50% of recipient mice from a lethal infection under the experimental conditions described. Conclusions. The 1976 swine flu vaccination induced cross-reactive HAI and NAI antibodies that were functionally protective in mice, suggesting that this vaccination campaign might have had a positive impact on older adults (≥50 years) in the United States during the 2009 H1N1 pandemic.